English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome (1) is described as an autoinflammatory disorder, similar to pyogenic sterile arthritis, pyoderma gangrenosum and acne (PAPA) syndrome, but without joint involvement, thereby satisfying the criteria of a disease entity distinct from infection, allergy and autoimmune disorders (2). A specific genetic mutation underlying PASH syndrome has not yet been identified. Treatment strategies for PASH syndrome and their efficacy have not been well documented. We report here a case of PASH syndrome that was successfully treated with granulocyte and monocyte adsorption apheresis (GMA) therapy, followed by adalimumab.

Pyoderma Gangrenosum, Acne and Suppurative Hidradenitis Syndrome Treated with Granulocyte and Monocyte Adsorption Apheresis